Alpha-Interferon
Neuroendocrine Cancer
The University of Texas Health Science Center, HoustonPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
50 Active assets in the Neuroendocrine Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE National Cancer Institute (NCI) | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 2 | B |
Everolimus AIO-Studien-gGmbH | Phase 2 | B |
Tarlatamab National Cancer Institute (NCI) | Phase 2 | B |
Carboplatin Phanes Therapeutics | Phase 2 | B |
View all 50 →
Same molecule, other indications
Alpha-Interferon is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →